Evidence map›Paper›PMID 28635300›Full record

ReviewAntioxidants & redox signaling2018

Pyridine Dinucleotides from Molecules to Man.

Joshua P Fessel, William M Oldham

Abstract readReview
In one paragraph

Review in Antioxidants & redox signaling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Energy metabolism in health and diseases.Signal transduction and targeted therapy · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. The Role of Glutamine and Glutaminase in Pulmonary Hypertension.Frontiers in cardiovascular medicine · 2022
    Review
  10. A Method to Monitor the NADInternational journal of molecular sciences · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Joshua P Fessel1 Department of Medicine, Vanderbilt University , Nashville, Tennessee.
William M Oldham2 Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts.
Harvard University · USVanderbilt University · US

Funding

Regulation of pulmonary vascular cell redox state by L-2-hydroxyglutarateK08HL128802 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI OLDHAM, WILLIAM MICHAEL · 2016 to 2020
$862k
Metabolic Reprogramming in Pulmonary Arterial HypertensionK08HL121174 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FESSEL, JOSHUA PATRICK · 2014 to 2018
$723k
NHLBI NIH HHS K08 HL121174NHLBI NIH HHS K08 HL128802
6 · The paper itself

Abstract

significancePyridine dinucleotides, nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), were discovered more than 100 years ago as necessary cofactors for fermentation in yeast extracts. Since that time, these molecules have been recognized as fundamental players in a variety of cellular processes, including energy metabolism, redox homeostasis, cellular signaling, and gene transcription, among many others. Given their critical role as mediators of cellular responses to metabolic perturbations, it is unsurprising that dysregulation of NAD and NADP metabolism has been associated with the pathobiology of many chronic human diseases. Recent Advances: A biochemistry renaissance in biomedical research, with its increasing focus on the metabolic pathobiology of human disease, has reignited interest in pyridine dinucleotides, which has led to new insights into the cell biology of NAD(P) metabolism, including its cellular pharmacokinetics, biosynthesis, subcellular localization, and regulation. This review highlights these advances to illustrate the importance of NAD(P) metabolism in the molecular pathogenesis of disease. CRITICAL ISSUES: Perturbations of NAD(H) and NADP(H) are a prominent feature of human disease; however, fundamental questions regarding the regulation of the absolute levels of these cofactors and the key determinants of their redox ratios remain. Moreover, an integrated topological model of NAD(P) biology that combines the metabolic and other roles remains elusive. FUTURE DIRECTIONS: As the complex regulatory network of NAD(P) metabolism becomes illuminated, sophisticated new approaches to manipulating these pathways in specific organs, cells, or organelles will be developed to target the underlying pathogenic mechanisms of disease, opening doors for the next generation of redox-based, metabolism-targeted therapies. Antioxid. Redox Signal. 28, 180-212.

Indexed as

Adenosine TriphosphateADP-ribosyl Cyclase 1Biosynthetic PathwaysCatalysisDisease SusceptibilityEnergy MetabolismHomeostasisHumansHydrolysisIntracellular SpaceMaleMitochondriaNADNADPNADPH OxidasesNitric Oxide SynthaseAdenosine TriphosphateADP-ribosyl Cyclase 1NADNADPNADPH OxidasesNitric Oxide SynthasepyridinePyridinesReactive Oxygen SpeciesmetabolismNADNADPPARPSIRT

Identifiers

PMID28635300
PMCPMC5737636
OpenAlexW2704271355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.